Medizone Intl. (fka MZEIQ)

[Joe_NY]

Medizone 8k: http://www.streetinsider.com/SEC+Filings/Form+8-K+MEDIZONE+INTERNATIONAL+For%3A+Sep+08/10878131.html

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2015

Medizone - Nevada

2-93277-D

(Commission File Number) 87-0412648

(IRS Employer Identification No.)
4000 Bridgeway, Suite 401, Sausalito, California 94965
Registrant's telephone number, including area code: [phone]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

On September 8, 2015, Medizone International, Inc. (“Registrant”) issued a press release summarizing recent commercial developments involving Registrant’s patented hospital disinfection system in the Kingdom of Saudi Arabia, including the execution of a letter of intent addressing the distribution of the system in the Kingdom of Saudi Arabia. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

The information contained in Item 7.01 of this Current Report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

The following exhibit is provided as part of the information furnished under Item 7.01 of this Current Report on Form 8-K

Press Release dated September 8, 2015

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medizone International, Inc.
By: Edwin G. Marshall
Chief Executive Officer
Date: September 9, 2015
AsepticSure Proposed for Saudi Arabia to help eliminate MERS-coronavirus
San Francisco, California, September 8, 2015. Medizone International, Inc. (The Company) (OTCBB: MZEI, OTCQB: MZEI), manufacturers of the AsepticSure® Hospital Disinfection System, are pleased to announce the recent sale and delivery of the initial two AsepticSure systems to Al-Hidaya International Medical Services Company headquartered in Jeddah, the Kingdom of Saudi Arabia. (https://alhidaya.com.sa ).

Al-Hidaya is under the leadership of Sheikh Saleh Salem M. Bahwini. Sheikh Bahwini has committed to helping rid the Kingdom of the MERS-coronavirus.

Al-Hidaya has sponsored a trip to the Kingdom for Medizone’s President and Director of Medical Affairs, Dr. Michael E. Shannon M.A.,M.Sc.,M.D. Dr. Shannon and his support team arrived in Jeddah the end of last week. Dr. Shannon and the team had been graciously invited to the Kingdom by the Minister of Health’s Office.

With the support of Dr. Shannon, Al-Hidaya is working with the regulatory agencies to satisfy any remaining requirements to bring AsepticSure into the Kingdom and allow us to contribute to reducing the incidence of MERS-coronavirus in Saudi hospitals with the use of AsepticSure. Dr. Shannon and his team will remain in Saudi Arabia until September 14th.

Prior to this trip Al-Hidaya International Medical Services Company had applied for Exclusive Distribution Rights for AsepticSure in the Kingdom. Medizone had responded with a Letter of Intent to Grant such rights, subject to the completion of a formal contractual agreement. Given Al-Hidaya’s demonstrated commitment and effort to date, Medizone believes the final contract details will be agreed to following current activities.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 415 331-0202
E: [e-mail]
For more information, visit:
http://www.medizoneint.com
Email: [e-mail]